1. Discuss the data presented at ASCO 2024 on long-term follow-up of patients receiving prophylactic tocilizumab for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study.
a. What is the background for using tocilizumab prior to administration of bispecific antibodies?
b. What methodology was used to study this cohort of patients?
c. What results were presented?
i. N=24
ii. Median follow-up: 8.1 months
iii. CRS occurred in 6 pts (25%; 2 grade 1, 4 grade 2, no grade ≥3)
iv. Reduced incidence of CRS with teclistamab vs overall MajesTEC-1 population

2. Please provide your key takeaways from this study. What are the implications of favorable safety results with the use of prophylactic tocilizumab?

3. In what patients are you currently using prophylactic tocilizumab? Who should be considered for it?

Related Content

Woman wearing Enfuse injector | image credit: Enable Injections

Subcutaneous Isatuximab Meets Primary End Points in Phase 3 Study for MM

January 9th 2025

Article

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

mRNA vaccines can boost T cell responses | image credit: myskin - stock.adobe.com

Study Advocates Immunological Value of COVID-19 Vaccination in MM

January 9th 2025

Article

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA vaccines could bolster immunity in this vulnerable population.

ICYMI: Highlights From ASH 2024

December 29th 2024

Article

The 66th American Society of Hematology (ASH) Annual Meeting & Exposition took place December 7-10, 2024, in San Diego, California; the 2025 meeting is currently scheduled to take place in Orlando, Florida, December 6-9.

ICYMI: Highlights From AMCP Nexus 2024

December 26th 2024

Article

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.